Loading…
← CockpitCompetitor Analysis › 688626.SS Xiangyu Medical Co., Ltd. Class AOpen in the cockpit ↗

Xiangyu Medical Co., Ltd. Class A688626.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese medical-device/consumables company; specific product focus not independently confirmed with confidence.

Momentum weak 33
Mkt cap
$877M
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$18.9M
20-day average traded
Fwd P/E
56.2×
forward earnings
ROIC−WACC
-6.5 pp
WACC 9.6%
Hurdle
n/a
no reverse DCF
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥37.63
1D-4.0%
1W-12.7%
1M-8.4%
3M-18.8%
6M-38.4%
YTD-37.8%
1Y-28.8%
ATR %6.5%
52w lowhigh60.4% off high

What Xiangyu Medical does

Chinese medical-device/consumables company; specific product focus not independently confirmed with confidence.

Where it sits in the supply chain

  • Health Care
  • Medical devices

Moat: none

Headquarters: China · Employees: 2,195

Xiangyu Medical at a glance

Size Xiangyu Medical (688626.SS) is a China Health Care company (Medical Specialties) with a market value of $877M, the 2416th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥37.63 on 18 Nov 2026.

Performance Over six months the shares fell 38.4%, against -13.6% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue fell 0.2% over the last twelve months (peer median +7.3%); the operating margin is 3.5% (peer median 9.4%).

Valuation It trades at 56.2× forward earnings against a peer median of 24.1× (4th most expensive of 15).

Capital Return on invested capital runs 6.5 points below its cost of capital (9.6% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 87688626.SS 63
Six months, rebased to 100: Xiangyu Medical against the median of its 20 peers (local-currency closes).

Xiangyu Medical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥769MCN¥764MCN¥740MCN¥737MCN¥486M
Revenue growth—+3%0%+52%—
Gross profitCN¥546MCN¥477MCN¥474MCN¥495MCN¥314M
EBITDAn/aCN¥83.0MCN¥96.0MCN¥193MCN¥61.1M
Net incomeCN¥79.0MCN¥78.2MCN¥103MCN¥227MCN¥125M
Free cash flow-CN¥7.38M-CN¥96.4M-CN¥259M-CN¥242MCN¥2.12M
Capital expenditureCN¥183MCN¥287MCN¥439MCN¥479MCN¥203M
Total debtCN¥341MCN¥628MCN¥368MCN¥43.1MCN¥25.5M

Quarterly statements and history in the cockpit →

Xiangyu Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%688767688575688277301580002658BVS688656301602AORTKURN36006033671187KIDS6888052906506880687780MCAPAMS688626.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Xiangyu Medical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×688767688575301580002658BVS688656AORTKURN360060336711877780688626.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Xiangyu Medical is the large dot.

Xiangyu Medical competitors and peer comparison

How Xiangyu Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Xiangyu Medical against its 20 peers (data as of 18 Nov 2026)
Measure688626.SSPeer medianRank in peer set
1-month return-8.4%-6.4%9th lowest of 21
6-month return-38.4%-13.6%lowest of 21
Distance from 52-week high-60.4%-41.7%4th lowest of 21
Revenue growth (TTM)-0.2%+7.3%5th lowest of 21
Operating margin3.5%9.4%5th lowest of 21
Forward P/E56.2×24.1×4th most expensive of 15
ROIC minus cost of capital-6.5 pp+1.5 pp5th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Xiangyu Medical 688626.SSChina$877M-38%0%4%56.2×n/an/a
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%37.0×n/an/a
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%30.7×2.0%+12.7%
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%n/an/an/a
Aidite (Qinhuangdao) Technology 301580.SZChina$888M-12%+17%18%26.2×19.3%+23.3%
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%22.4×16.8%+2.9%
Bioventus BVSUnited States$895M-3%+4%10%13.0×7.5%+12.1%
HOB Biotech 688656.SSChina$858M-33%+6%7%166.9×37.6%+12.4%
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%n/a11.1%+4.6%
Artivion AORTUnited States$905M-18%+14%5%383.6×n/an/a
Kuros Biosciences KURN.SWSwitzerland$907M-12%+41%6%70.5×n/an/a
Modern Dental 3600.HKHong Kong$844M+24%+12%22%8.5×-7.1%+11.3%
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%7.9×-14.6%-1.3%
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%13.1×-6.4%+6.6%
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%n/an/an/a
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%n/a35.6%+17.1%
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%n/a32.6%+21.0%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%n/an/an/a
Menicon 7780.TJapan$944M+26%+6%9%20.9×n/an/a
MedCap MCAP.STSweden$811M-4%+17%15%25.8×2.7%+20.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%20.7×20.0%+21.4%

Questions

Which companies are Xiangyu Medical's closest peers?
The cockpit's peer set: Hangzhou Biotest Biotech (688767.SS), Shenzhen YHLO Biotech (688575.SS), Tinavi Medical Technologies (688277.SS), Aidite (Qinhuangdao) Technology (301580.SZ), Beijing SDL Technology (002658.SZ), Bioventus (BVS), HOB Biotech (688656.SS), Shantou Institute of Ultrasonic Instruments (301602.SZ).
Is Xiangyu Medical expensive compared with its peers?
On forward p/e it trades at 56.2× against a peer median of 24.1×, 4th most expensive of 15 in its peer set.
How has Xiangyu Medical stock performed?
Over six months to 18 Nov 2026 the shares returned -38.4% against -13.6% for the median peer; over one year -28.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.